HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
about
Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthNRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.The role of oxidative stress on breast cancer development and therapy.Translational issues for human corneal endothelial tissue engineering.Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases.Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer.The Roles of 4β-Hydroxywithanolide E from Physalis peruviana on the Nrf2-Anti-Oxidant System and the Cell Cycle in Breast Cancer Cells.Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer.The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 Cells
P2860
Q35626610-220754C0-1768-4C5E-9167-C5A93C368068Q36387554-19B21922-F7D5-495E-AB18-A0F5E17A919EQ37684348-A6A2AC63-837B-4003-8FB6-6E5CB5FD34ECQ37689036-765879FE-4228-4FD1-B4CF-4E66CB6B94E5Q37745486-CA00039D-B9F8-4166-AE05-ED5AE592DBAEQ38713186-4CECCE68-2F98-4913-B8F2-6C0745825A7FQ38816097-FB1D2B64-21D2-4072-839F-6D7A1742C4A4Q38849205-3C018C94-EFBA-4EFA-8336-38625F5CB528Q38894913-87EAF6AA-6514-4264-8A6C-E1A5578EF5FAQ42321189-63C0B9FE-5AA9-4C3D-A0E4-7543AC93FBE9Q46149679-14C31644-D259-4CBD-B4D7-4F04155F22EEQ46558958-F760D472-4517-430F-92A2-D6621C9D771FQ55286461-0DD70439-BDB0-47B9-89E8-B07865864D52Q55309854-F4B33331-EAC7-4342-AF64-6C7C7345EF64Q57136097-B7AC21B1-B2E1-4DBF-936C-D60E7CABDBB2
P2860
HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@ast
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@en
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@nl
type
label
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@ast
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@en
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@nl
prefLabel
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@ast
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@en
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@nl
P2093
P2860
P356
P1433
P1476
HER2 confers drug resistance o ...... of NRF2 by direct interaction
@en
P2093
Hee Jeong Kim
Hyo Jin Kang
Yeon-Sun Seong
Young Bin Hong
Young-Joo Jang
P2860
P2888
P356
10.1038/SREP07201
P407
P50
P577
2014-12-03T00:00:00Z
P5875
P6179
1025472087